UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Broad spectrum vasopressors: a new approach to the initial management of septic shock?

Critical care (London, England), 2019-04, Vol.23 (1), p.124-124, Article 124

2019

Volltextzugriff (PDF)

Angiotensin converting enzyme defects in shock: implications for future therapy

Critical care (London, England), 2018-10, Vol.22 (1), p.274-274, Article 274

2018

Volltextzugriff (PDF)

Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock

Critical care (London, England), 2020-02, Vol.24 (1), p.43-43, Article 43

2020

Volltextzugriff (PDF)

LJ000328, a novel ALK2/3 kinase inhibitor, represses hepcidin and significantly improves the phenotype of IRIDA

Haematologica (Roma), 2020-08, Vol.105 (8), p.e385-e388

2020

Volltextzugriff (PDF)

2-deoxy-d-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo

Cancer research (Chicago, Ill.), 2004, Vol.64 (1), p.31-34

2004

Volltextzugriff (PDF)

Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial

Annals of intensive care, 2019-06, Vol.9 (1), p.63-10, Article 63

2019

Volltextzugriff (PDF)

Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas

Journal of clinical oncology, 2001-10, Vol.19 (19), p.3918-3928

2001

Volltextzugriff (PDF)

Angiotensin II for the treatment of high-output shock 3 (ATHOS-3): Protocol for a phase III, double-blind, randomised controlled trial

Critical care and resuscitation, 2017-03, Vol.19 (1), p.43-49

2017

Volltextzugriff (PDF)

Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II

Critical care medicine, 2018-06, Vol.46 (6), p.949-957

2018

Volltextzugriff (PDF)

Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial

American journal of respiratory and critical care medicine, 2020-11, Vol.202 (9), p.1253-1261

2020

Volltextzugriff (PDF)

Angiotensin II for the Treatment of Vasodilatory Shock

The New England journal of medicine, 2017-08, Vol.377 (5), p.419-430

2017

Volltextzugriff (PDF)

Therapeutic Opportunities for Hepcidin in Acute Care Medicine

Critical care clinics, 2019-04, Vol.35 (2), p.357-374

2019

Volltextzugriff (PDF)

Bridging the gap between basic and applied biology: towards preclinical translation

Disease models & mechanisms, 2013-05, Vol.6 (3), p.559-561

2013

Volltextzugriff (PDF)

A Novel Alkylating Agent, Glufosfamide, Enhances the Activity of Gemcitabine In Vitro, In Vivo

Neoplasia (New York, N.Y.), 2007-08, Vol.9 (8), p.625-633

2007

Volltextzugriff (PDF)

Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas

Journal of clinical oncology, 2000-03, Vol.18 (6), p.1316-1323

2000

Volltextzugriff (PDF)

Synthetic Human Angiotensin II in Pediatric Patients With Vasodilatory Shock: A Report on Two Patients

Critical care explorations, 2019-08, Vol.1 (8), p.e0036

2019

Volltextzugriff (PDF)

The authors reply

Critical care medicine, 2019-03, Vol.47 (3), p.e271-e272

2019

Volltextzugriff (PDF)

Pharmacodynamic evaluation of intragastric pH and implications for famotidine dosing in the prophylaxis of non-steroidal anti-inflammatory drug induced gastropathy-a proof of concept analysis

Journal of drug assessment (London, U.K.), 2014-01, Vol.3 (1), p.20-27

2014

Volltextzugriff (PDF)

A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma

Cancer chemotherapy and pharmacology, 2008-05, Vol.61 (6), p.1019-1026

2008

Volltextzugriff (PDF)

The authors reply

Critical care medicine, 2019-03, Vol.47 (3), p.e271

2019

Volltextzugriff (PDF)

In Vivo Anticoagulant Properties of a Novel Nucleotide-Based Thrombin Inhibitor and Demonstration of Regional Anticoagulation in Extracorporeal Circuits

Blood, 1993-06, Vol.81 (12), p.3271-3276

1993

Volltextzugriff (PDF)

Normal thymic cortical epithelial cells developmentally regulate the expression of a B-lineage transformation-associated antigen

Immunogenetics (New York), 1988-03, Vol.27 (3), p.180-186

1988

Volltextzugriff (PDF)

Effect of 2-Deoxyglucose, a Glycolytic Inhibitor, on the ATP Levels and Viability of B Lymphocytes from Subjects with Chronic Lymphocytic Leukemia (CLL)

Blood, 2004-11, Vol.104 (11), p.4810-4810

2004

Volltextzugriff (PDF)

Bone marrow stromal cell lines with lymphopoietic activity express high levels of a pre-B neoplasia-associated molecule

Cell, 1987-03, Vol.48 (6), p.1009-1021

1987

Volltextzugriff (PDF)

Synthetic Human Angiotensin II in Pediatric Patients With Vasodilatory Shock: A Report on Two Patients

Critical care explorations, 2019, Vol.1 (8), p.e0036-e0036

2019

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(32)
Berichte
(2)

Sprache

Englisch
(34)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Broad spectrum vasopressors: a new approach to the initial management of septic shock?

Angiotensin converting enzyme defects in shock: implications for future therapy

Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock

LJ000328, a novel ALK2/3 kinase inhibitor, represses hepcidin and significantly improves the phenotype of IRIDA

2-deoxy-d-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo

Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial

Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas

Angiotensin II for the treatment of high-output shock 3 (ATHOS-3): Protocol for a phase III, double-blind, randomised controlled trial

Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II

Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial

Angiotensin II for the Treatment of Vasodilatory Shock

Therapeutic Opportunities for Hepcidin in Acute Care Medicine

Bridging the gap between basic and applied biology: towards preclinical translation

A Novel Alkylating Agent, Glufosfamide, Enhances the Activity of Gemcitabine In Vitro, In Vivo

Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas

Synthetic Human Angiotensin II in Pediatric Patients With Vasodilatory Shock: A Report on Two Patients

The authors reply

Pharmacodynamic evaluation of intragastric pH and implications for famotidine dosing in the prophylaxis of non-steroidal anti-inflammatory drug induced gastropathy-a proof of concept analysis

A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma

The authors reply

In Vivo Anticoagulant Properties of a Novel Nucleotide-Based Thrombin Inhibitor and Demonstration of Regional Anticoagulation in Extracorporeal Circuits

Normal thymic cortical epithelial cells developmentally regulate the expression of a B-lineage transformation-associated antigen

Effect of 2-Deoxyglucose, a Glycolytic Inhibitor, on the ATP Levels and Viability of B Lymphocytes from Subjects with Chronic Lymphocytic Leukemia (CLL)

Bone marrow stromal cell lines with lymphopoietic activity express high levels of a pre-B neoplasia-associated molecule

Synthetic Human Angiotensin II in Pediatric Patients With Vasodilatory Shock: A Report on Two Patients

Suchergebnisse filtern